Table 41LMWH vs UFH: Clinical summary of findings

OutcomeLMWHUFHRelative riskAbsolute effectQuality
All cause mortality (at 3 months) – all patients115/3226 (3.6%)139/2949 (4.7%)RR 0.78 (0.61 to 0.99)10 fewer per 1000 (from 0 fewer to 18 fewer)LOW
Subgroup: Acute PE19/459 (4.1%)24/472 (5.1%)RR 0.82 (0.45 to 1.47)9 fewer per 1000 (from 28 fewer to 24 more)LOW
Subgroup: DVT or PE73/1903 (3.8%)75/1605 (4.7%)RR 0.86 (0.63 to 1.19)7 fewer per 1000 (from 17 fewer to 9 more)LOW
Subgroup: DVT only (symptomatic PE excluded)23/864 (2.7%)40/872 (4.6%)RR 0.59 (0.36 to 0.97)19 fewer per 1000 (from 1 fewer to 29 fewer)LOW
VTE related mortality (at 3 months)16/2952 (0.54%)18/2659 (0.68%)RR 0.82 (0.44 to 1.55)1 fewer per 1000 (from 4 fewer to 4 more)LOW
Subgroup: Acute PE3/459 (0.65%)4/472 (0.85%)RR 0.8 (0.2 to 3.21)2 fewer per 1000 (from 7 fewer to 19 more)LOW
Subgroup: DVT or PE11/1708 (0.64%)9/1400 (0.64%)RR 1.01 (0.45 to 2.29)0 more per 1000 (from 4 fewer to 8 more)LOW
Subgroup: DVT only (symptomatic PE excluded)2/785 (0.25%)5/787 (0.64%)RR 0.46 (0.1 to 2.02)3 fewer per 1000 (from 6 fewer to 6 more)LOW
Recurrent VTE (at 3 months)104/3127 (3.3%)128/2822 (4.3%)RR 0.77 (0.6 to 1)10 fewer per 1000 (from 17 fewer to 0 more)LOW
Major bleeding (at 3 months)45/1941 (2.3%)64/1958 (3.3%)RR 0.72 (0.5 to 1.04)9 fewer per 1000 (from 16 fewer to 1 more)LOW
Fatal bleeding (at 3 months)7/2658 (0.3%)10/2340 (0.4%)RR 0.55 (0.21 to 1.41)2 fewer per 1000 (from 3 fewer to 2 more)LOW
Intracranial bleeding (at 3 months)1/1775 (0.1%)5/1675 (0.3%)RR 0.46 (0.14 to 1.5)2 fewer per 1000 (from 3 fewer to 1 more)VERY LOW
PTSN=41N=43-MD 2.45 lower (6.16 lower to 1.26 higher)VERY LOW
Heparin induced thrombocytopenia6/1124 (0.5%)5/1127 (0.4%)RR 1.19 (0.4 to 3.49)1 more per 1000 (from 3 fewer to 11 more)VERY LOW
Quality of lifeN=70--No statistically significant difference, except for social and physical functioning while on therapy (1–2 weeks).VERY LOW

From: 7, Pharmacological interventions

Cover of Venous Thromboembolic Diseases
Venous Thromboembolic Diseases: The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing [Internet].
NICE Clinical Guidelines, No. 144.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.